Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2015 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Endometriosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Endometriosis - Pipeline Review, H2 2015', provides an overview of the Endometriosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Endometriosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Endometriosis Overview 8 Therapeutics Development 9 Pipeline Products for Endometriosis - Overview 9 Pipeline Products for Endometriosis - Comparative Analysis 10 Endometriosis - Therapeutics under Development by Companies 11 Endometriosis - Therapeutics under Investigation by Universities/Institutes 13 Endometriosis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Endometriosis - Products under Development by Companies 18 Endometriosis - Products under Investigation by Universities/Institutes 20 Endometriosis - Companies Involved in Therapeutics Development 21 AbbVie Inc. 21 Addex Therapeutics Ltd 22 APAvadis Biotechnologies Srl 23 Astellas Pharma Inc. 24 Bayer AG 25 Dongkook Pharmaceutical Co., Ltd. 26 ElexoPharm GmbH 27 EndoCeutics, Inc. 28 Enteris BioPharma, Inc. 29 Euroscreen S.A. 30 Evotec AG 31 Forendo Pharma Oy 32 GlaxoSmithKline Plc 33 Kissei Pharmaceutical Co., Ltd. 34 Lipicard Technologies Limited 35 Nippon Shinyaku Co., Ltd. 36 Orphagen Pharmaceuticals, Inc. 37 Philogen S.p.A. 38 Repros Therapeutics Inc. 39 SK Chemicals Co., Ltd. 40 Takeda Pharmaceutical Company Limited 41 ValiRx Plc 42 Endometriosis - Therapeutics Assessment 43 Assessment by Monotherapy Products 43 Assessment by Combination Products 44 Assessment by Target 45 Assessment by Mechanism of Action 48 Assessment by Route of Administration 50 Assessment by Molecule Type 52 Drug Profiles 54 (anastrozole + levonorgestrel) - Drug Profile 54 acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 55 ADX-68692 - Drug Profile 56 ASP-1707 - Drug Profile 57 BAY-1128688 - Drug Profile 58 bentamapimod - Drug Profile 59 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 61 Drugs for Endometriosis - Drug Profile 62 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 63 elagolix sodium - Drug Profile 64 epelsiban besylate - Drug Profile 66 ESN-364 - Drug Profile 68 EVE-104 - Drug Profile 69 FP-5677 - Drug Profile 70 goserelin - Drug Profile 71 KLH-2109 - Drug Profile 72 leuprolide acetate - Drug Profile 73 LT-6121 - Drug Profile 74 Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 75 NCE-403 - Drug Profile 76 NS-580 - Drug Profile 77 Peptides for Cancer and Endometriosis - Drug Profile 78 Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 79 PGL-2001 - Drug Profile 80 Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 81 relugolix - Drug Profile 82 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 83 Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 84 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 85 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 86 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 87 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 88 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 89 SR-16234 - Drug Profile 90 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 91 telapristone acetate - Drug Profile 92 Tetravil - Drug Profile 95 triptorelin pamoate - Drug Profile 97 VAL-201 - Drug Profile 98 vilaprisan - Drug Profile 100 VPE-001 - Drug Profile 101 VPEA-004 - Drug Profile 102 Endometriosis - Recent Pipeline Updates 103 Endometriosis - Dormant Projects 117 Endometriosis - Discontinued Products 119 Endometriosis - Product Development Milestones 120 Featured News & Press Releases 120 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 127 Disclaimer 128
List of Tables
Number of Products under Development for Endometriosis, H2 2015 12 Number of Products under Development for Endometriosis - Comparative Analysis, H2 2015 13 Number of Products under Development by Companies, H2 2015 15 Number of Products under Investigation by Universities/Institutes, H2 2015 16 Comparative Analysis by Late Stage Development, H2 2015 17 Comparative Analysis by Clinical Stage Development, H2 2015 18 Comparative Analysis by Early Stage Development, H2 2015 19 Comparative Analysis by Unknown Stage Development, H2 2015 20 Products under Development by Companies, H2 2015 21 Products under Development by Companies, H2 2015 (Contd..1) 22 Products under Investigation by Universities/Institutes, H2 2015 23 Endometriosis - Pipeline by AbbVie Inc., H2 2015 24 Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2015 25 Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2015 26 Endometriosis - Pipeline by Astellas Pharma Inc., H2 2015 27 Endometriosis - Pipeline by Bayer AG, H2 2015 28 Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015 29 Endometriosis - Pipeline by ElexoPharm GmbH, H2 2015 30 Endometriosis - Pipeline by EndoCeutics, Inc., H2 2015 31 Endometriosis - Pipeline by Enteris BioPharma, Inc., H2 2015 32 Endometriosis - Pipeline by Euroscreen S.A., H2 2015 33 Endometriosis - Pipeline by Evotec AG, H2 2015 34 Endometriosis - Pipeline by Forendo Pharma Oy, H2 2015 35 Endometriosis - Pipeline by GlaxoSmithKline Plc, H2 2015 36 Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 37 Endometriosis - Pipeline by Lipicard Technologies Limited, H2 2015 38 Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2015 39 Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015 40 Endometriosis - Pipeline by Philogen S.p.A., H2 2015 41 Endometriosis - Pipeline by Repros Therapeutics Inc., H2 2015 42 Endometriosis - Pipeline by SK Chemicals Co., Ltd., H2 2015 43 Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 44 Endometriosis - Pipeline by ValiRx Plc, H2 2015 45 Assessment by Monotherapy Products, H2 2015 46 Assessment by Combination Products, H2 2015 47 Number of Products by Stage and Target, H2 2015 49 Number of Products by Stage and Mechanism of Action, H2 2015 52 Number of Products by Stage and Route of Administration, H2 2015 54 Number of Products by Stage and Molecule Type, H2 2015 56 Endometriosis Therapeutics - Recent Pipeline Updates, H2 2015 106 Endometriosis - Dormant Projects, H2 2015 120 Endometriosis - Dormant Projects (Contd..1), H2 2015 121 Endometriosis - Discontinued Products, H2 2015 122
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
